H.C. Wainwright Remains a Buy on Caladrius Biosciences

By Jason Carr

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Caladrius Biosciences (NASDAQ: CLBS) today and set a price target of $12. The company’s shares opened today at $4.26.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -6.6% and a 37.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

Caladrius Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $12.

See today’s analyst top recommended stocks >>

The company has a one-year high of $6.35 and a one-year low of $2.63. Currently, Caladrius Biosciences has an average volume of 70.46K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Caladrius Biosciences, Inc. operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease.